GeneDx Holdings Corp. Class A Common Stock Q2 2025 Earnings Recap

GeneDx reported record revenue exceeding $100 million in Q2 2025, driven by robust growth in its core genetic testing services and strategic expansions into new clinical markets.

Key Takeaways

• Achieved over $100 million in revenue for the first time in a single quarter, highlighting strong business momentum.
• Captured nearly one-third of pediatric neurologists as new exome and genome ordering providers, indicating deepening market penetration.
• Initiated outreach to pediatric immunologists and expanded into the NICU, targeting a $1 billion opportunity with rapid genomic testing.
• Positioned well for growth following new AAP guidelines allowing pediatricians to utilize genomic sequencing as a first-tier test for developmental delays, potentially transforming the pediatric health landscape.
• Emphasized competitive edge through a unique data set and advanced AI-driven testing capabilities, reinforcing GeneDx’s market leadership in genetic diagnostics.